Oncotelic Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -118.0% | -118.0% | -39.8% |
| FY2022 | 26.3% | 26.3% | 14.1% |
| FY2023 | -65.2% | -65.2% | -26.3% |
| FY2024 | -54.8% | -54.8% | -17.0% |
| FY2025 | 94.9% | 94.9% | 63.4% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -118.0% | -118.0% | -39.8% |
| FY2022 | 26.3% | 26.3% | 14.1% |
| FY2023 | -65.2% | -65.2% | -26.3% |
| FY2024 | -54.8% | -54.8% | -17.0% |
| FY2025 | 94.9% | 94.9% | 63.4% |